Albireo Pharma Inc (ALBO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
Nov 03, 2022: Albireo announces 2022 SPARK grant winners
Aug 22, 2022: Albireo pharma releases corporate update
Aug 15, 2022: Albireo Reports Q2 2022 Financial Results and Business Update
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Albireo Pharma Inc (Albireo), formerly Biodel Inc, It focuses on the development and commercialization of novel bile acid modulators for treatment of orphan pediatric liver diseases, gastrointestinal (GI) disorders and other diseases. Its pipeline products include odevixibat (A4250) intended for treatment of progressive familial intrahepatic cholestasis (PFIC), biliary atresia, alagille syndrome and other cholestaticc; A3384 for bile acid malabsorption; and elobixibat for nonalcoholic steatohepatitis (NASH). Elobixibat is approved in Japan for the treatment of chronic constipation. The company is investigating bile acid modulator for nonalcoholic steatohepatitis (NASH) and other preclinical trials for the treatment of adult liver diseases. It operates in the US, the UK, and Sweden. Albireo is headquartered in Boston, Massachusetts, the US.Albireo Pharma Inc Key Recent Developments
Nov 08, 2022: Albireo Reports Q3 2022 Financial Results and Business UpdateNov 03, 2022: Albireo announces 2022 SPARK grant winners
Aug 22, 2022: Albireo pharma releases corporate update
Aug 15, 2022: Albireo Reports Q2 2022 Financial Results and Business Update
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company- Albireo Pharma Inc - Key Facts
- Albireo Pharma Inc - Key Employees
- Albireo Pharma Inc - Key Employee Biographies
- Albireo Pharma Inc - Major Products and Services
- Albireo Pharma Inc - History
- Albireo Pharma Inc - Company Statement
- Albireo Pharma Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Company Overview
- Albireo Pharma Inc - Business Description
- R&D Overview
- Albireo Pharma Inc - Corporate Strategy
- Albireo Pharma Inc - SWOT Analysis
- SWOT Analysis - Overview
- Albireo Pharma Inc - Strengths
- Albireo Pharma Inc - Weaknesses
- Albireo Pharma Inc - Opportunities
- Albireo Pharma Inc - Threats
- Albireo Pharma Inc - Key Competitors
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
- Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
- Albireo Pharma Inc, Recent Deals Summary
- Nov 08, 2022: Albireo Reports Q3 2022 Financial Results and Business Update
- Nov 03, 2022: Albireo announces 2022 SPARK grant winners
- Aug 22, 2022: Albireo pharma releases corporate update
- Aug 15, 2022: Albireo Reports Q2 2022 Financial Results and Business Update
- Aug 10, 2022: Albireo Appoints New Members to Board of Directors
- Jun 07, 2022: Albireo to Present New Data at the 54th Annual Meeting of ESPGHAN
- May 16, 2022: Albireo Reports Q1 2022 Financial Results and Business Update
- Feb 22, 2022: Albireo Reports Q4 and Year-End 2021 Financial Results and Business Update
- Methodology
- Ratio Definitions
- About the Publisher
- Contact the Publisher
- Disclaimer
- Albireo Pharma Inc, Key Facts
- Albireo Pharma Inc, Key Employees
- Albireo Pharma Inc, Key Employee Biographies
- Albireo Pharma Inc, Major Products and Services
- Albireo Pharma Inc, History
- Albireo Pharma Inc, Subsidiaries
- Albireo Pharma Inc, Key Competitors
- Albireo Pharma Inc, Ratios based on current share price
- Albireo Pharma Inc, Annual Ratios
- Albireo Pharma Inc, Interim Ratios
- Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
- Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
- Albireo Pharma Inc, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- Albireo Pharma Inc, Performance Chart (2017 - 2021)
- Albireo Pharma Inc, Ratio Charts
- Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
- Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Sandoz Inc
- Shire Pharmaceuticals International UC
- Par Pharmaceutical Holdings Inc
- Mirum Pharmaceuticals Inc
- GSK plc
- Upsher-Smith Laboratories LLC
- Shire Pharmaceuticals International UC
- Sandoz Inc
- GSK plc
- Par Pharmaceutical Holdings Inc
- Mirum Pharmaceuticals Inc
- Upsher-Smith Laboratories LLC
